Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04284761 · ClinicalTrials.gov registry record · Phase 1
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
A Phase 1 study, sponsored by Alessa Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04284761 is a Phase 1 study that has completed, run by Alessa Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT04284761, a Phase 1 study, has completed, sponsored by Alessa Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.
Interventions
- COMBINATION_PRODUCT Bicalutamide implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-10-11 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04284761
The ClinicalTrials.gov registry entry for NCT04284761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alessa Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bicalutamide implant is the first listed.
NCT04284761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04284761 about?
NCT04284761 is a clinical study titled "A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer". Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether the Biolen is safe.
What is the current status of trial NCT04284761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-10-11. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT04284761?
The interventions under investigation include: Bicalutamide implant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04284761?
This trial is sponsored by Alessa Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.